Q-omics provides the consensus-scored NDUFC2 profile across patient tissues and cancer cell-line models. NDUFC2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, NDUFC2 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, NDUFC2 protein abundance shows 23,061 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, BLCA, and GBM as cancer lineages where NDUFC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFC2 survival associations across molecular data types. NDUFC2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFC2 RNA expression–survival associations across cancer types. High NDUFC2 expression shows unfavorable associations in KICH and ACC, but favorable associations in THCA, LUSC, KIRC and OV. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KICH as the clearest survival context for NDUFC2 RNA expression.
This table summarizes NDUFC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFC2 shows lower tumor expression in KIRP and KIRC and higher tumor expression in BLCA, STAD, BRCA and LIHC. The BLCA box plot shows higher NDUFC2 RNA expression in tumor versus normal tissue (log2 FC = +0.662, t-test p < 0.001).
This table shows molecular features associated with NDUFC2 in patient tissues and cancer cell lines. In patient samples, NDUFC2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
